Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

Laura Carter Biography and Net Worth

Insider of Gossamer Bio

Laura Carter, Ph.D. has served as our Chief Scientific Officer since April 2021, previously having served as our Senior Vice President, Research & Translational Biology since joining Gossamer in March 2019. Dr. Carter has over 20 years of industry experience spanning target identification and validation activities through Phase 2 clinical trials in multiple therapeutic areas. Prior to joining Gossamer, she was Senior Vice President, Biology at Lycera Corporation, where she led the development of several immunology and immuno-oncology clinical product candidates. Before joining Lycera, she was a scientific director in the respiratory, inflammation and autoimmunity group at MedImmune, where she was responsible for overseeing research and development of treatments for autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis. Prior to MedImmune, she was a senior research investigator in the inflammation biology and translational science department at Array Biopharma. She started her career in industry at Wyeth, where, among other accomplishments, her basic science studies were critical in identifying and characterizing the negative regulatory role of PD-1:PD-L interactions on T cell function in vitro and in vivo.

What is Laura Carter's net worth?: The estimated net worth of Laura Carter is at least $65,441.28 as of March 16th, 2023. Dr. Carter owns 76,263 shares of Gossamer Bio stock worth more than $65,441 as of April 16th. This net worth evaluation does not reflect any other assets that Dr. Carter may own. Learn More about Laura Carter's net worth.
How do I contact Laura Carter?: The corporate mailing address for Dr. Carter and other Gossamer Bio executives is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. Gossamer Bio can also be reached via phone at (858) 684-1300 and via email at [email protected]. Learn More on Laura Carter's contact information.
Has Laura Carter been buying or selling shares of Gossamer Bio?: Laura Carter has not been actively trading shares of Gossamer Bio in the last ninety days. Most recently, Laura Carter sold 6,029 shares of the business's stock in a transaction on Thursday, March 16th. The shares were sold at an average price of $1.10, for a transaction totalling $6,631.90. Following the completion of the sale, the insider now directly owns 76,263 shares of the company's stock, valued at $83,889.30. Learn More on Laura Carter's trading history.
Who are Gossamer Bio's active insiders?: Gossamer Bio's insider roster includes Laura Carter (Insider), Bryan Giraudo (CFO), and Luisa Salter-Cid (Insider). Learn More on Gossamer Bio's active insiders.
Are insiders buying or selling shares of Gossamer Bio?: During the last year, Gossamer Bio insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $112,000.00. During the last year, insiders at the sold shares 4 times. They sold a total of 35,434 shares worth more than $42,022.32. The most recent insider tranaction occured on March, 27th when CFO Bryan Giraudo sold 6,430 shares worth more than $7,458.80. Insiders at Gossamer Bio own 9.5% of the company. Learn More about insider trades at Gossamer Bio.
Information on this page was last updated on 3/27/2024.

Laura Carter Insider Trading History at Gossamer Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/16/2023	Sell	6,029	$1.10	$6,631.90	76,263
10/24/2022	Sell	4,876	$12.07	$58,853.32	82,292
7/15/2022	Buy	6,934	$7.21	$49,994.14	87,168
7/1/2022	Sell	8,808	$8.25	$72,666.00	80,234
5/4/2022	Sell	1,262	$7.20	$9,086.40	89,042
3/16/2022	Sell	5,002	$8.28	$41,416.56
10/25/2021	Sell	2,377	$12.25	$29,118.25

Laura Carter Buying and Selling Activity at Gossamer Bio

Gossamer Bio Company Overview

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Today's Range

Now: $0.83

$0.83

$0.87

50 Day Range

MA: $1.19

$0.86

$1.51

2 Week Range

Now: $0.83

$0.45

$1.88

Volume

406,067 shs

Average Volume

1,194,781 shs

Market Capitalization

$187.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71